Cargando…

[(68)Ga]DOTATOC PET/CT Radiomics to Predict the Response in GEP-NETs Undergoing [(177)Lu]DOTATOC PRRT: The “Theragnomics” Concept

SIMPLE SUMMARY: The radiological response assessment of neuroendocrine tumors (NET) to peptide receptor radionuclide therapy (PRRT) using [(177)Lu]DOTATOC is still suboptimal due to the high variability in targeted somatostatin receptor 2 (SSTR-2) expression and histological heterogeneity among pati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laudicella, Riccardo, Comelli, Albert, Liberini, Virginia, Vento, Antonio, Stefano, Alessandro, Spataro, Alessandro, Crocè, Ludovica, Baldari, Sara, Bambaci, Michelangelo, Deandreis, Desiree, Arico’, Demetrio, Ippolito, Massimo, Gaeta, Michele, Alongi, Pierpaolo, Minutoli, Fabio, Burger, Irene A., Baldari, Sergio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870649/ https://www.ncbi.nlm.nih.gov/pubmed/35205733 http://dx.doi.org/10.3390/cancers14040984

Ejemplares similares

Extravasation of [(177)Lu]Lu-DOTATOC: case report and discussion
por: Arveschoug, Anne Kirstine, et al.
Publicado: (2020)

Prognostic Value of the Largest Lesion Size for Progression-Free Survival in Patients with NET Undergoing Salvage PRRT with [(177)Lu]Lu-DOTATOC
por: Galler, Markus, et al.
Publicado: (2022)

(68)Ga-DOTATOC PET/CT-Based Radiomic Analysis and PRRT Outcome: A Preliminary Evaluation Based on an Exploratory Radiomic Analysis on Two Patients
por: Liberini, Virginia, et al.
Publicado: (2021)

The Dependence of Renal (68)Ga[Ga]-DOTATOC Uptake on Kidney Function and Its Relevance for Peptide Receptor Radionuclide Therapy with (177)Lu[Lu]-DOTATOC
por: Gühne, Falk, et al.
Publicado: (2021)

The Prognostic Value of the De Ritis Ratio for Progression-Free Survival in Patients with NET Undergoing [(177)Lu]Lu-DOTATOC-PRRT: A Retrospective Analysis
por: Ruhwedel, Tristan, et al.
Publicado: (2021)

(90)Y/(177)Lu-DOTATOC: From Preclinical Studies to Application in Humans
por: Uccelli, Licia, et al.
Publicado: (2021)

The therapeutic efficacy of (177)Lu-DOTATATE/DOTATOC in advanced neuroendocrine tumors: A meta-analysis
por: Wang, Li-fan, et al.
Publicado: (2020)

Practical kidney dosimetry in peptide receptor radionuclide therapy using [(177)Lu]Lu-DOTATOC and [(177)Lu]Lu-DOTATATE with focus on uncertainty estimates
por: Staanum, Peter Frøhlich, et al.
Publicado: (2021)

[(177)Lu]Lu-DOTA-TATE versus standard of care in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs): a cost-consequence analysis from an Italian hospital perspective
por: Spada, Francesca, et al.
Publicado: (2021)

Addition of (131)I-MIBG to PRRT ((90)Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
por: Bushnell, David L., et al.
Publicado: (2021)

Relevance of Volumetric Parameters Applied to [(68)Ga]Ga-DOTATOC PET/CT in NET Patients Treated with PRRT
por: Urso, Luca, et al.
Publicado: (2023)

Effect of Peptide Dose on Radiation Dosimetry for Peptide Receptor Radionuclide Therapy with (177)Lu-DOTATOC: A Pilot Study
por: Prasad, Vikas, et al.
Publicado: (2021)

Improving Overall Survival and Quality of Life in Patients with Prostate Cancer and Neuroendocrine Tumors Using (177)Lu-iPSMA and (177)Lu-DOTATOC: Experience after 905 Treatment Doses
por: Luna-Gutiérrez, Myrna, et al.
Publicado: (2023)

Three-dimensional Monte Carlo-based voxel-wise tumor dosimetry in patients with neuroendocrine tumors who underwent (177)Lu-DOTATOC therapy
por: Goetz, Th. I., et al.
Publicado: (2020)

[(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study
por: Baum, Richard P., et al.
Publicado: (2016)

The utility of gallium-68 DOTATOC PET/CT in lymphangioleiomyomatosis
por: Gaffney, Brian, et al.
Publicado: (2021)

(64)Cu-DOTATOC PET-CT in Patients with Neuroendocrine Tumors
por: Mirzaei, Siroos, et al.
Publicado: (2019)

Predictive and Prognostic Role of Pre-Therapy and Interim 68Ga-DOTATOC PET/CT Parameters in Metastatic Advanced Neuroendocrine Tumor Patients Treated with PRRT
por: Durmo, Rexhep, et al.
Publicado: (2022)

Nephrotoxicity after PRRT with (177)Lu-DOTA-octreotate
por: Bergsma, Hendrik, et al.
Publicado: (2016)

[(68)Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning
por: Gehler, Barbara, et al.
Publicado: (2009)

Improved radiolabeling of DOTATOC with trivalent radiometals for clinical application by addition of ethanol
por: Eppard, Elisabeth, et al.
Publicado: (2016)

Pindborg Tumor—An Uncommon Odontogenic Tumor Detected by 68Ga-DOTATOC
por: Herden, Anna, et al.
Publicado: (2022)

Glucose Metabolism Modification Induced by Radioligand Therapy with [(177)Lu]Lu/[(90)Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial
por: Urso, Luca, et al.
Publicado: (2022)

Role of (68)Ga-DOTATOC PET/CT in the Evaluation of Primary Pulmonary Carcinoids
por: Jindal, Tarun, et al.
Publicado: (2010)

Evaluation of the Possible Utilization of (68)Ga-DOTATOC in Diagnosis of Adenocarcinoma Breast Cancer
por: Zolghadri, Samaneh, et al.
Publicado: (2018)

The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers
por: Liberini, Virginia, et al.
Publicado: (2021)

Impact of dead time on quantitative (177)Lu-SPECT (QSPECT) and kidney dosimetry during PRRT
por: Desy, Alessandro, et al.
Publicado: (2020)

Splenosis Mimicking Relapse of a Neuroendocrine Tumor at Gallium-68-DOTATOC PET/CT
por: Treglia, Giorgio, et al.
Publicado: (2013)

Usefulness of (68)Ga-DOTATOC PET/CT to localize the culprit tumor inducing osteomalacia
por: Lee, Dong Yun, et al.
Publicado: (2021)

Prospective data-driven respiratory gating of [(68)Ga]Ga-DOTATOC PET/CT
por: Sigfridsson, Jonathan, et al.
Publicado: (2021)

Thyroid metastasis from lung carcinoid detected by (68)Ga-DOTATOC PET/CT
por: Albano, Domenico, et al.
Publicado: (2021)

(68)Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis
por: Boughdad, Sarah, et al.
Publicado: (2021)

Accuracy and reproducibility of simplified QSPECT dosimetry for personalized (177)Lu-octreotate PRRT
por: Del Prete, Michela, et al.
Publicado: (2018)

Prostate Cancer Biochemical Recurrence Resulted Negative on [(68)Ga]Ga-PSMA-11 but Positive on [(18)F]Fluoromethylcholine PET/CT
por: Laudicella, Riccardo, et al.
Publicado: (2022)

Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with $^152$Tb-DOTATOC
por: Baum, Richard P, et al.
Publicado: (2017)

First intraindividual comparison of contrast-enhanced MRI, FET- and DOTATOC- PET in patients with intracranial meningiomas
por: Dittmar, Jan Oliver, et al.
Publicado: (2017)

Intrapancreatic accessory spleen false positive to 68Ga-Dotatoc: case report and literature review
por: Lancellotti, Francesco, et al.
Publicado: (2019)

Correction: (68)Ga-DOTATOC PET/CT to detect immune checkpoint inhibitor-related myocarditis
Publicado: (2022)

Optic Nerve Sheath Meningiomas: Solving Diagnostic Challenges with (68)Ga-DOTATOC PET/CT
por: Horowitz, Tatiana, et al.
Publicado: (2023)

The Safety and Efficacy of the Repeated PRRT with [(90)Y]Y/[(177)Lu]Lu-DOTATATE in Patients with NET
por: Zemczak, Anna, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cqlj14rp8mgis450qk69tdtca0